The overall goal of the proposed research is to come to a biochemical understanding of how a small viral protein, Tat, controls the expression of the HIV genome. The focus of the study will be on a cyclin dependent kinase, P-TEFb, that is a key factor controlling elongation by RNA polymerase II and is specifically required for Tat transactivation. HIV-1 Tat interacts with PTEFb and enhances its function at the HIV-LTR. First, human P-TEFb will be characterized by determining its subunit structure. PITALRE, the kinase subunit, and several putative cyclin subunits will be analyzed to determine if they are in complexes with active P-TEFb. Next, the requirements for efficient interaction between P-TEFb with Tat will be examined using in vitro binding studies with immobilized Tat and P-TEFb complexes and in vivo immunoprecipitation experiments. The potential requirement for protein or RNA cofactors will be addressed. Finally, a series of experiments to address the biochemical mechanism of Tat mediated enhancement of the action of P-TEFb will be performed. These will include a detailed optimization of Tat transactivation in vitro using extracts from both HeLa and Jurkat cells. The effect of Tat on the association of P-TEFb, factor 2, the SPT4/SPT5 complex, and other factors with the transcription complex will be determined. The reason that the HIV-LTR seems to be especially sensitive to PTEFb inhibitors will also be explored. In addition, a yeast system will be designed that may allow the study of Tat transactivation and the interaction of P-TEFb and Tat in vivo. The HIV epidemic is a growing national as well as international concern and the most effective treatments are those incorporating a combinatorial use of different drugs. Understanding Tat transactivation may lead to the discovery of new drugs to battle AIDS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI043691-04
Application #
6373940
Study Section
AIDS and Related Research Study Section 3 (ARRC)
Program Officer
Bridges, Sandra H
Project Start
1998-07-01
Project End
2003-06-30
Budget Start
2001-07-01
Budget End
2003-06-30
Support Year
4
Fiscal Year
2001
Total Cost
$219,255
Indirect Cost
Name
University of Iowa
Department
Biochemistry
Type
Schools of Medicine
DUNS #
041294109
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Peterlin, B Matija; Price, David H (2006) Controlling the elongation phase of transcription with P-TEFb. Mol Cell 23:297-305
Adamson, Todd E; Shore, Sarah M; Price, David H (2003) Analysis of RNA polymerase II elongation in vitro. Methods Enzymol 371:264-75
Shore, Sarah M; Byers, Sarah A; Maury, Wendy et al. (2003) Identification of a novel isoform of Cdk9. Gene 307:175-82
Chao, S H; Price, D H (2001) Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793-9
Lis, J T; Mason, P; Peng, J et al. (2000) P-TEFb kinase recruitment and function at heat shock loci. Genes Dev 14:792-803
Price, D H (2000) P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II. Mol Cell Biol 20:2629-34
Chao, S H; Fujinaga, K; Marion, J E et al. (2000) Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345-8